KR20210131371A - 1-(1-옥소-1,2-디하이드로이소퀴놀린-5-일)-5-(트리플루오로메틸)-n-(2-(트리플루오로메틸)피리딘-4-일)-1h-피라졸-4-카복사미드 일수화물의 결정질 형태 - Google Patents

1-(1-옥소-1,2-디하이드로이소퀴놀린-5-일)-5-(트리플루오로메틸)-n-(2-(트리플루오로메틸)피리딘-4-일)-1h-피라졸-4-카복사미드 일수화물의 결정질 형태 Download PDF

Info

Publication number
KR20210131371A
KR20210131371A KR1020217029765A KR20217029765A KR20210131371A KR 20210131371 A KR20210131371 A KR 20210131371A KR 1020217029765 A KR1020217029765 A KR 1020217029765A KR 20217029765 A KR20217029765 A KR 20217029765A KR 20210131371 A KR20210131371 A KR 20210131371A
Authority
KR
South Korea
Prior art keywords
compound
crystalline form
disease
condition
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020217029765A
Other languages
English (en)
Korean (ko)
Inventor
카리나 레이즈
크리스토프 레오나드 킴페
로버트 마이클 기어트만
하오주안 웨이
펑 저우
Original Assignee
얀센 파마슈티카 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 얀센 파마슈티카 엔.브이. filed Critical 얀센 파마슈티카 엔.브이.
Publication of KR20210131371A publication Critical patent/KR20210131371A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020217029765A 2019-02-22 2020-02-20 1-(1-옥소-1,2-디하이드로이소퀴놀린-5-일)-5-(트리플루오로메틸)-n-(2-(트리플루오로메틸)피리딘-4-일)-1h-피라졸-4-카복사미드 일수화물의 결정질 형태 Withdrawn KR20210131371A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019075834 2019-02-22
CNPCT/CN2019/075834 2019-02-22
PCT/EP2020/054485 WO2020169736A1 (en) 2019-02-22 2020-02-20 Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate

Publications (1)

Publication Number Publication Date
KR20210131371A true KR20210131371A (ko) 2021-11-02

Family

ID=69723907

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217029765A Withdrawn KR20210131371A (ko) 2019-02-22 2020-02-20 1-(1-옥소-1,2-디하이드로이소퀴놀린-5-일)-5-(트리플루오로메틸)-n-(2-(트리플루오로메틸)피리딘-4-일)-1h-피라졸-4-카복사미드 일수화물의 결정질 형태

Country Status (21)

Country Link
US (1) US12269813B2 (enExample)
EP (1) EP3927696B1 (enExample)
JP (1) JP2022523368A (enExample)
KR (1) KR20210131371A (enExample)
CN (1) CN113474339B (enExample)
AU (1) AU2020226723B2 (enExample)
BR (1) BR112021016400A2 (enExample)
CA (1) CA3129623A1 (enExample)
EA (1) EA202192320A1 (enExample)
EC (1) ECSP21067828A (enExample)
ES (1) ES2966132T3 (enExample)
IL (1) IL285675A (enExample)
JO (1) JOP20210227A1 (enExample)
MA (1) MA55019A (enExample)
MX (1) MX2021010133A (enExample)
PE (1) PE20212067A1 (enExample)
PH (1) PH12021552018A1 (enExample)
SG (1) SG11202108909SA (enExample)
TW (1) TW202045495A (enExample)
UY (1) UY38592A (enExample)
WO (1) WO2020169736A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
US12404260B2 (en) 2019-04-11 2025-09-02 Janssen Pharmaceutica Nv Pyridine rings containing derivatives as MALT1 inhibitors
BR112023003106A2 (pt) 2020-08-21 2023-04-04 Janssen Pharmaceutica Nv Forma amorfa de um inibidor de malt1 e formulações do mesmo
BR112023017689A2 (pt) 2021-03-03 2023-11-14 Janssen Pharmaceutica Nv Método de tratamento de uma condição com o uso de uma dose terapeuticamente eficaz do inibidor de malt1 jnj-67856633 (1-(1-oxo-1,2-di-hidroisoquinolin-5-il)-5-(trifluorometil)-n­(2-(trifluorometil)piridin-4-il)-1h-pirazol-4-carboxamida)
EP4301365A1 (en) 2021-03-03 2024-01-10 Janssen Pharmaceutica NV Combination therapy using a malt1 inhibitor and a btk inhibitor
AU2022326183A1 (en) * 2021-08-09 2024-03-28 Janssen Pharmaceutica Nv Compositions for use in treating b-cell malignancies
WO2025073968A1 (en) 2023-10-06 2025-04-10 Ionctura Sa Combination of roginolisib with a malt1-gls inhibitor

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007525183A (ja) 2003-04-30 2007-09-06 アジェンシス， インコーポレイテッド 癌の処置および検出において有用な１０９ｐ１ｄ４と称される、核酸および対応タンパク質
WO2007111904A2 (en) * 2006-03-22 2007-10-04 Vertex Pharmaceuticals Incorporated C-met protein kinase inhibitors for the treatment of proliferative disorders
WO2008092292A1 (en) 2007-01-17 2008-08-07 The Hong Kong University Of Science And Technology Isoquinolone compounds as subtype-selective agonists for melatonin receptors mt1 and mt2
WO2011036885A1 (ja) * 2009-09-25 2011-03-31 武田薬品工業株式会社 複素環化合物
US20120071497A1 (en) 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
KR101580714B1 (ko) 2010-06-03 2016-01-04 파마싸이클릭스 엘엘씨 브루톤 티로신 인산화효소(ｂｔｋ)의 억제제의 용도
CN102947270B (zh) 2010-06-22 2015-04-08 巴斯夫欧洲公司 制备4-羟基吡啶的方法
MX2014014531A (es) * 2012-05-31 2015-04-08 Hoffmann La Roche Derivados de aminoquinazolina y piridopirimidina.
HUE044351T2 (hu) 2014-05-28 2019-10-28 Novartis Ag Új pirazolo-pirimidin származékok és azok alkalmazása MALT1 inhibitorként
EP3177366A4 (en) 2014-08-08 2018-04-04 Pharmacyclics LLC Bruton's tyrosine kinase inhibitor combinations and uses thereof
US10835524B2 (en) * 2015-06-24 2020-11-17 University Of Florida Research Foundation, Incorporated Compositions for the treatment of pancreatic cancer and uses thereof
CA3003820A1 (en) 2015-11-13 2017-05-18 Novartis Ag Novel pyrazolo pyrimidine derivatives
EP3423452B1 (en) 2016-03-01 2025-05-07 University of Maryland, Baltimore Wnt signaling pathway inhibitors for treatments of disease
TWI795381B (zh) * 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
EP3576744A1 (en) 2017-02-01 2019-12-11 Medivir Aktiebolag Therapeutic applications of malt1 inhibitors
US11571427B2 (en) 2017-12-28 2023-02-07 The General Hospital Corporation Targeting the CBM signalosome complex induces regulatory T cells to inflame the tumor microenvironment
WO2019161921A1 (de) 2018-02-23 2019-08-29 Industrieanlagen-Betriebsgesellschaft Mbh Vorrichtung zum erzeugen eines magnetfelds, insbesondere für ein induktives ladesystem, und primäreinrichtung eines induktiven ladesystems zum dynamischen aufladen von fahrzeugen
WO2021138298A1 (en) 2019-12-30 2021-07-08 Rheos Medicines, Inc. Malt1 modulators and uses thereof
BR112023003106A2 (pt) * 2020-08-21 2023-04-04 Janssen Pharmaceutica Nv Forma amorfa de um inibidor de malt1 e formulações do mesmo

Also Published As

Publication number Publication date
CN113474339A (zh) 2021-10-01
US20220127249A1 (en) 2022-04-28
CA3129623A1 (en) 2020-08-27
EP3927696A1 (en) 2021-12-29
PH12021552018A1 (en) 2022-09-19
JOP20210227A1 (ar) 2023-01-30
IL285675A (en) 2021-10-31
WO2020169736A1 (en) 2020-08-27
TW202045495A (zh) 2020-12-16
ECSP21067828A (es) 2021-11-18
AU2020226723B2 (en) 2025-01-23
UY38592A (es) 2020-08-31
JP2022523368A (ja) 2022-04-22
CN113474339B (zh) 2025-02-25
SG11202108909SA (en) 2021-09-29
AU2020226723A1 (en) 2021-08-19
PE20212067A1 (es) 2021-10-26
ES2966132T3 (es) 2024-04-18
MX2021010133A (es) 2021-09-23
EP3927696B1 (en) 2023-10-18
EA202192320A1 (ru) 2021-11-16
MA55019A (fr) 2021-12-29
US12269813B2 (en) 2025-04-08
BR112021016400A2 (pt) 2021-10-13
EP3927696C0 (en) 2023-10-18

Similar Documents

Publication Publication Date Title
KR20210131371A (ko) 1-(1-옥소-1,2-디하이드로이소퀴놀린-5-일)-5-(트리플루오로메틸)-n-(2-(트리플루오로메틸)피리딘-4-일)-1h-피라졸-4-카복사미드 일수화물의 결정질 형태
TW202110835A (zh) 固態形式
CN111770914B (zh) 作为神经激肽-1受体拮抗剂的化合物及其用途
TW202110836A (zh) 固態形式
WO2023059598A1 (en) Combination therapies of kras g12d inhibitors with shp-2 inhibitors
US11918585B2 (en) Formulations of an AXL/MER inhibitor
JP5924453B2 (ja) 二環式含窒素芳香族ヘテロ環アミド化合物
TWI771280B (zh) 經取代之5,6-二氫-6-苯基苯并[f]異喹啉-2-胺化合物之固體形式
KR20140040671A (ko) 아프레피탄트 l-프롤린 조성물 및 공결정
JP2014533719A (ja) アプレピタントｌ−プロリン溶媒和化合物−組成物及び共結晶
US20220348565A1 (en) Pharmaceutical compounds
EA045924B1 (ru) Кристаллическая форма моногидрата 1-(1-оксо-1,2-дигидроизохинолин-5-ил)-5-(трифторметил)-n-(2-(трифторметил)пиридин-4-ил)-1h-пиразол-4-карбоксамида
HK40052643A (en) Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate
RU2684278C1 (ru) Фумарат пиридиламина и его кристаллы
TW201829398A (zh) 酪胺酸蛋白激酶調節劑、晶型及其用途
US20240140908A1 (en) A pharmaceutical salt of an arylpyrrole derivative
TW202342041A (zh) 一種藥物組合物及所含活性成分化合物的製備方法
CN118451071A (zh) 表皮生长因子受体抑制剂的结晶多晶型物及其组合物和方法
HK40052420A (en) Formulations of an axl/mer inhibitor
HK40052420B (en) Formulations of an axl/mer inhibitor
HK40029219B (en) Compounds as neurokinin-1 receptor antagonists and uses thereof
WO2019001551A1 (zh) 一种咪唑并异吲哚类衍生物游离碱的晶型及其制备方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20210915

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20250306

WITB Written withdrawal of application